Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells by Yi Zhu et al.
Zhu et al. Cancer Cell International 2013, 13:54
http://www.cancerci.com/content/13/1/54PRIMARY RESEARCH Open AccessApigenin promotes apoptosis, inhibits invasion
and induces cell cycle arrest of T24 human
bladder cancer cells
Yi Zhu, Yeqing Mao, Hong Chen, Yiwei Lin, Zhenghui Hu, Jian Wu, Xin Xu, Xianglai Xu, Jie Qin and Liping Xie*Abstract
Background: Apigenin (4’,5,7-trihydroxyflavone) was recently shown effective in inhibiting several cancers. The aim
of this study was to investigate the effect and mechanism of apigenin in the human bladder cancer cell line T24 for
the first time.
Methods: T24 cells were treated with varying concentrations and time of apigenin. Cell viability was evaluated by
MTT assay. Cell motility and invasiveness were assayed by Matrigel migration and invasion assay. Flow cytometry
and western blot analysis were used to detect cell apoptosis, cell cycle and signaling pathway.
Results: The results demonstrated that apigenin suppressed proliferation and inhibited the migration and invasion
potential of T24 bladder cancer cells in a dose- and time-dependent manner, which was associated with induced
G2/M Phase cell cycle arrest and apoptosis. The mechanism of action is like to involve PI3K/Akt pathway and Bcl-2
family proteins. Apigenin increased caspase-3 activity and PARP cleavage, indicating that apigenin induced
apoptosis in a caspase-dependent way.
Conclusions: These findings suggest that apigenin may be an effective way for treating human bladder cancer.
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Apigenin, one of the most common flavonoids, is widely
distributed in many fruits and vegetables, including parsley,
onions, orange, tea, chamomile, wheat sprouts and in
some seasonings [1]. Apigenin has potential uses in cancer
prevention and therapy, and it suppresses cell growth
against many human cancer cell lines, including breast,
colon, skin, thyroid, leukemia, and prostate cancer cells
[2-5]. Unlike other structurally related flavonoids, apigenin
is non-mutagenic [6]. Although previous reports have
shown the inhibitory effect of apigenin on other human
cancer cells, there are few reports indicating the inhibitory
effect on human bladder cancer cells.
Bladder cancer is the most common malignant tumor
of the urinary tract. Worldwide, bladder cancer is the
seventh most common cancer. An average of 386,300* Correspondence: xielp@zjuem.zju.edu.cn
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reproduction in any medium, provided the ornew cases of urinary bladder cancer are diagnosed
worldwide every year, accounting for 150,200 deaths [7].
In recent decades, bladder cancer was shown of a rising
overall incidence [8]. In most cases of nonmuscle invasive
bladder cancer, tumors are treated initially with TURBT
(Transurethral Resection of Bladder Tumor). A careful
cystoscopic examination of the entire urethra and all
bladder surfaces precedes resection. Intravesical therapy
can also be employed in an expectant way as opposed
to an induction course alone to provide long-term
immunostimulation or chemotoxicity and thereby prevent
disease recurrence [9,10]. Our earlier studies have shown
that EGCG [11] and resveratrol [12] may be an important
chemopreventive agent for the management of bladder
cancer. Here we proved for the first time that
apigenin could induce apoptosis and cell cycle arrest of
bladder cells.
Besides many natural agents extracts like EGCG,
resveratrol and genistein which are proved of the ability
of cancer chemoprevention, apigenin is another agent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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whether apigenin decreases the ability of migration and
invasion of T24 bladder cells and is apoptotic of T24
bladder cells by inhibiting PI3K/Akt pathway, activating
caspases and induces cell cycle arrest. Finally, we
showed that in T24 bladder cancer cells apigenin
upregulates Bax and Bad, activates caspase-3 and poly
(ADPribose) polymerase (PARP), inhibits PI3K/Akt
pathway, downregulates antiapoptotic protein Bcl-2 and
Bcl-x, and leads to G2/M cell cycle arrest.
Results
Apigenin inhibits cell growth in T24 cells
The MTTassay demonstrated that apigenin treatment with
the vehicle DMSO (1 ul/mL) and varying concentrations
(10–80 μM) and times (24 to 72 hours), resulted in a
dose- and time-dependent inhibition of T24 cell growth,
compared to untreated controls. As is shown in Figure 1,
there was no significant difference between untreated
control and vehicle control which meant DMSO wasn’t
able to affect the proliferation of T24 cells. When the
treated concentration was 10 μM, the viability of cells
changed very little. Just because of this, we use the
concentration of 0–20 μM to complete the migration and
invasion assay. With the increasing of the concentration
and time, there appeared an obvious reduction in cell
viability, especially with the concentration of 40 and
80 μM. The inhibitory concentration 50% values for
apigenin treatment were estimated to be 82.5, 52.9, and
43.8 μM for 24, 48, and 72 h, respectively. These data
indicated that apigenin exerts a significant inhibitory effect
on T24 cells.
Apigenin inhibits T24 cell migration and invasion
As the low concentration of apigenin didn’t induce a
significant death of T24 cells, we treated the T24 cells
with 0–20 μM to detect whether the low concentration ofFigure 1 Cytotoxicity effects of apigenin in T24 bladder cancer
cells. Cell proliferation and viability were determined by an MTT assay.
Reduced cell viability with apigenin treatment (1 uL/mL DMSO, Apigenin
of 10–80 μM) was observed at 24, 48 and 72 h. The data are presented
as mean ± SD.apigenin decreased the migration and invasion potential
of T24 cells. As shown in Figure 2, apigenin-treated cells
exhibited a significant decrease in both motility and
invasion compared to untreated control.
Apigenin induces apoptosis in T24 cells
To determine whether the observed apigenin-induced cell
death in T24 cells occurred via induction of apoptosis, we
assessed the effect of apigenin treatment on apoptosis in
the next series of experiments in T24 cells. The cells were
treated with varying concentration of apigenin (0–80 μM)
for 24 h and analyzed by flow cytometry. Compared with
untreated control, apigenin treatment resulted in apoptosis
in a dose-dependent manner (Figure 3A and B). The
percent of apoptotic cells increased to 22.2% under the
treatment of apigenin in the concentration of 80 μM.
Caspase-3 activation and PARP cleavage are characteristic
indicators of apoptosis. As a downstream effector in the
caspase cascade, when caspase-3 is activated, it induces an
irreversible apoptosis [13]. PARP cleavage, procaspase-3
and active caspase-3 protein were detected by western
blot. In apigenin-treated T24 cell samples, cleaved PARP
and active caspase-3 increased, while procaspase-3
decreased in a dose-dependent manner after 24 h
treatment (Figure 3C).
Apigenin induces G2/M phase cell cycle arrest
Treatment of T24 cells with apigenin resulted in dose- and
time-dependent inhibition of cell growth and induced
apoptosis, compared with their untreated controls. We
considered the possibility that this may involve an arrest of
cells at specific check point in the cell cycle. We therefore
assessed the effect of apigenin on cell cycle perturbations.
Compared with the untreated controls, apigenin treatment
leaded to an appreciable arrest of T24 cells in G2/M phase
of the cell cycle. Cell cycle analysis showed that the G2/M
phase population of the control cells was 14.45% and the
percentage of cells in G2/M phase significantly increased
after 24 h treatment of apigenin of different concentrations.
(Figure 4A) (20.19%, 24.9%, 27.7%, 30.68%, and 37.94%
cells at 20, 40, 80, 120, and 160 μM concentrations of
apigenin, respectively) after 24 h treatment. This increase
in G2/M phase cell population was accompanied with a
concomitant decrease of cell number in G1 phase of the
cell cycle (Figure 4B).
Apigenin modulates Akt pathway
Akt acts as an anti-apoptotic signaling molecule and is
a good candidate for mediating the PI3K-dependent
cell-survival responses [14]. To determine whether
apigenin induces apoptosis by modulation of this pathway,
we investigated the expression of total Akt and phosphor-
ylation of Akt after treatment with apigenin of different
concentrations (0–80 μM) for 24 h. Western blot analysis
Figure 2 Effect of apigenin on T24 cell invasion and migration. Cells treated with 0–20 μM apigenin were induced to move or invade
through uncoated or Matrigel-coated transwell membranes. After 24 hours, cells were fixed, stained, and counted. A, a representative image;
B, shows the quantitation of one experiment done in triplicate. * P < 0.05 versus untreated control, ** P < 0.01 versus untreated control.
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(p-Akt) is decreased in a dose-dependent way, while no
significant difference existed in total Akt (Figure 5A).
At the same time, the protein PI3K and PDK, which
phosphorylates Akt, also showed a decrease. These
results indicate PI3K/Akt pathway plays an importantFigure 3 Apigenin treatment induces dose-dependent apoptosis in T
induced by treatment with apigenin in T24 bladder cancer cells. Cells treat
annexin V and PI and analyzed by flow cytometry. The gate setting disting
(bottom right), and late apoptotic (top right) cells. (B) The percent of total
* P < 0.05, ** P < 0.01 versus untreated control. (C) Apigenin treatment activ
expression of proteins in treated cells was analyzed by Western blotting as
independent experiments with identical results.role in the apigenin-induced apoptosis in T24 bladder
cancer.
To further investigate the modulation of apigenin on
PI3K-Akt pathway, T24 cells were pretreated with
20 μM PI3 kinase inhibitor LY294002 for 30 min. Cells
were than treated with 40 μM apigenin for another 24 h.24 human bladder cancer cells. (A) Dose-dependent apoptosis
ed with various concentrations of apigenin were double-stained with
uished between living (bottom left), necrotic (top left), early apoptotic
apoptotic cells was quantified from three independent experiments.
ates caspase-3 and PARP in T24 human bladder cancer cells. The
detailed in Methods. A representative blot is shown from three
Figure 4 Cell cycle analysis of T24 bladder cancer cells treated with apigenin. (A)Cells were treated with different concentrations of
apigenin for 24 h and then stained with propidium iodide. The DNA content was analyzed by flow cytometry. G1, S, and G2/M indicate cell cycle
phase. (B) It shows an obvious G2/M phase arrest with a concomitant decrease of cell number in G1 phase of the cell cycle. The percent of G2/M
phase was quantified from three independent experiments. * P < 0.05, ** P < 0.01 versus untreated control.
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blotting. As shown in Figure 5B, PI3K inhibitor, LY294002
decreased the protein levels of cleaved PARP and active
casepase-3, suggesting that apigenin-induced apoptosis
depended on PI3K-Akt activity.
Apigenin alters Bcl-2 family protein expression in T24 cells
As is known, Bcl-2 family plays a crucial role in apoptosis.
The change of the ratio of proapoptotic protein versus
antiapoptotic proteins of Bcl-2 family such as Bax and
Bcl-2 will activate the mitochondrial apoptotic pathway.
In addition, several kinases have been shown to phorylate
and inactivate Bad, and Akt is one of them [15]. ThereforeFigure 5 Expression of proteins changed in cells treated with differen
(A) Apigenin reduced the expression phosphorylation of Akt, PI3K and PDK
cells was treated with 20 μM PI3 kinase inhibitor LY294002 for 30 min and
decreased the protein levels of cleaved PARP and active casepase-3 which
anti-apoptotic gene products Bcl-2 and Bcl-xL but upregulated the express
shown from three independent experiments with identical results.we next studied the dose-dependent effects of apigenin on
the constitutive protein levels of Bcl-2 family in T24 cells.
The Western blot analysis showed a significant increase in
the expression of pro-apoptotic protein Bax and Bad,
while in sharp contrast, the protein expression of Bcl-2
and Bcl-xl was significantly decreased by apigenin treat-
ment in a dose-dependent manner (Figure 5C). The results
revealed evidence that apigenin-induced apoptosis was
involved with Bcl-2 family.
Discussion
In this study, we showed that apigenin, a nonmutagenic
antitumor flavonoid, exhibits an inhibition action on T24t concentrations of apigenin or apigenin and LY294002 for 24 h.
significantly, but the expression of total Akt had no change. (B) T24
then with 40 μM apigenin for another 24 h. PI3K inhibitor, LY294002
were activated by apigenin. (C) Apigenin inhibited the expression of
ion of apoptotic gene product Bax and Bad. A representative blot is
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chemopreventive/therapeutic potential of apigenin against
bladder cancer by induction of apoptosis, migration and
invasion inhibition and cell cycle arrest. Akt, also known
as Protein Kinase B (PKB), is a serine/threonine-specific
protein kinase that plays a key role in multiple cellular
processes such as glucose metabolism, apoptosis, cell
proliferation, transcription and cell migration. The
mechanism by which Akt protects cells from death is
likely to be multifactorial, because Akt directly phosphory-
lates several components of the cell-death machinery [16].
Some of the mechanisms involve the phosphorylation and
inactivation of the apoptotic mediators Bad, caspase-9,
FKHRL1, and IKK [17-23]. Besides, Akt is known to be a
downstream of PI3K to regulate many biological processes.
In our study, we confirmed that apigenin treatment in T24
cells induced apoptosis and inhibited the phosphorylation
of Akt in a dose-dependent manner which meant the
apigenin-treated apoptosis was involved with PI3K/Akt
pathway. Notably, our data suggest that the mechanism
of the tumor suppressive effect involved inhibition of
PI3K/Akt signaling pathways. In this study, the reason
why the PI3K/Akt expression level was markedly decreased
by apigenin treatment is not clear. An earlier study on
head and neck carcinomas suggests that apigenin targets
EGFR, which is upstream of PI3K/Akt [24]. In a future
study, the correlation between apigenin and EGFR expres-
sion levels in bladder cancer needs to be examined.
The Bcl-2 protein family consists of both pro-apoptotic
(Bax and Bad) and anti-apoptotic (Bcl-2) proteins that
regulate mitochondrial outer membrane integrity, cyto-
chrome c release, and caspase activation leading to apop-
tosis. Previous studies showed that with the activation of
the PI3K/Akt pathway the expression of Bcl-2 family
increased [25], and Akt inhibits apoptosis through
mitochondrial pathways [26]. Shifting the balance of
Bcl-2 family members toward pro-apoptotic effects will
activate caspase-3 and executes the apoptotic program
[27]. Therefore we investigated the effect of apigenin
on Bcl-2 family. The present study indicates that
apigenin treatment upregulates pro-apoptotic proteins
Bax and Bad while downregulates anti-apoptotic proteins
Bcl-2 and Bcl-xl protein. Change of the Bcl-2 family
induces the release of cytochrome c from mitochondria
into cytosol and cytosolic cytochrome c then binds to
Apaf-1 and leads to the activation of caspase-3 and PARP
[28]. In our research, we also confirmed that apigenin
activated caspase-3 and leaded to PARP cleavage. Thus
our study proved apigenin treatment induces apoptosis in
T24 cells via PI3K/Akt pathway and Bcl-2 family.
Cell cycle arrest and apoptosis represent two effective
mechanisms involved in the induction of cell death [29]. It
is well established that loss of key cell cycle checkpoints
is a hallmark of cancer cells, leading to abnormalproliferation and facilitating oncogenic transformation
[30]. Observations have shown that apigenin is a potent
inhibitor of cell-cycle progression in a number of different
cell lines [31,32]. We also measured the effect of apigenin
on cell cycle of T24 cells and found that apigenin leads to
a G2/M phase arrest. The similar results were observed in
human colon and breast carcinomas [4]. In the present
study, G2/M phase increased from 14.45% up to 37.94%,
with almost 2.6 folds increasing, in a dose-dependent way,
which indicated the apigenin-induced cell growth inhibition
was involved with cell cycle arrest. Although Lepley
DM, et al. [32] have proved a G1 arrest by apigenin in
human diploid fibroblast, we observed G2/M arrest in
apigenin-treated T24 cells. The difference between these
results might be attributed to the cell types tested. Previous
studies have shown that PI3K/Akt pathway could regulate
expression of G2/M-related proteins to influence the
progression of G2 to mitosis phase. Expression of active
form of Akt led to an increase in the protein and mRNA
level of Cdk1, whereas Akt dominant negative mutation
inhibited cell proliferation by inducing G2/M arrest [33].
Taken together, apigenin may inhibit cellular proliferation
by inducing a cell cycle arrest at G2/M in T24 bladder
cancer cells and probably via PI3K/Akt pathway.Conclusion
In conclusion, our study demonstrates that apigenin can
induce dose- and time-dependent cell death and apoptosis
and inhibit migration and invasion ability in T24 bladder
cancer cells. Apigenin leads to apoptosis via PI3K/Akt
pathway, regulation of Bcl-2 family and activation of
caspase-3 and PARP. Additionally, Apigenin also causes
G2/M phase arrest. All these results indicate that apigenin
can be used as a chemopreventive agent in bladder cancer.
To the best of our knowledge, this is the first report showing
the antitumor effect of apigenin in bladder cancer
in vitro. However, further investigations of the mechanism
of apigenin-treated cell inhibition are necessary.Methods
Reagents and cell culture
Apigenin (≥ 99% pure) and MTT were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). The annexin
V-FITC apoptosis detection kit was from BD Biosciences
(SanJose, CA, USA). Primary antibodies to Bcl-2, Bax,
Bcl-xL, pro caspase-3, active caspase-3, GAPDH and
poly(ADP-ribose) polymerase (PARP), and secondary
antibodies were purchased from Santa-Cruz Biotechnology,
Inc. (Santa Cruz, CA). Antibodies to Akt, phosphorylated
Akt, PDK, PI3K and Bad were purchased from Cell Signaling
Technology (Beverly, MA). The bicinchoninic acid pro-
tein assay kit was obtained from Pierce Biotechnology
(Rockford, IL).
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from the Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). The cells were cul-
tured in RPMI-1640 medium (HyClone, Logan, UT, USA)
supplemented with 10% heat-inactivated FBS (JRH
Biosciences, Lenexa, KS, USA), 100 U/ml penicillin, and
100 mg/L strep-tomycin. Cultures were maintained in a
humidified atmosphere of 5% CO2 at 37°C.
Cell viability assay
The effect of apigenin on the viability of T24 cells was
evaluated by MTT assay. Approximately 10 × 104 T24
cells were seeded on 96-well plates. After overnight
incubation, the cells were treated with vehicle DMSO
(1 uL/mL) and different concentrations of apigenin
(0–80 μM in DMSO) for 24 hours. After incubation for
the indicated time, MTT (20 μL of 5 mg/mL) was added
to each well and incubated at 37°C for 4 h, after which the
MTT solution in the medium was removed. To achieve
solubilization of the formazan crystal formed in viable
cells, 150 μL DMSO was added to each well before the
absorbance at 490 nm was measured using an MRX II
absorbance reader (Dynex Technologies, Chantilly, VA,
USA). Results were expressed as a percentage of growth,
with 100% representing control cells treated with DMSO
alone.
In vitro invasion and motility assays
The invasion and motility assays were done as previously
described [34] with some minor modifications. Cells
were plated in a 6-well plate at a density of 8 × 104 cells/
well. After overnight incubation, cells were treated with
different concentrations of apigenin (0–20 μM in DMSO)
for 24 hours and harvested. The treated and the control
cells were suspended in medium at a concentration of
4 × 105 cells/mL, and 0.2 mL of each was added to the
top chamber of uncoated (for motility assays) or
Matrigel-coated (for invasion assays) PET membranes
(24-well insert, 8-μm pore size; Millipore, Bedford,
MA). Medium (0.6 mL) supplemented with 20% fetal
bovine serum was added to each well of the plate to act
as a chemoattractant in the lower chamber. Cells were
incubated for 24 hours, and those that did not migrate
through the pores were removed by scraping the upper
surface of the membrane with a cotton swab. Cells that
had migrated to the lower surface of the membrane
were fixed for 5 min in 100% methanol and stained with
0.1% crystal violet for 2 min. These experiments were
done in triplicate and performed a minimum of three
times.
Cell apoptosis assay
The extent of apoptosis was evaluated by annexin V-FITC
and flow cytometry. Cells were grown at a density of1 × 106 cells in six-well culture dishes and were treated
with different concentrations of apigenin (0–80 μM in
DMSO) for 24 h. Following treatment, the cells were
harvested, washed twice with pre-chilled PBS, and
resuspended in 1× binding buffer at a concentration of
1 × 106 cells/ml. One hundred microliters of such solution
was mixed with 5 μL annexin V-FITC and 5 μL propidium
iodide for 15 min, and then 400 μL 1× binding buffer was
added. Analysis was carried out using a FC500 flow
cytometer with CXP software (Beckman Coulter, Fullerton,
CA, USA) within 1 h. The percentage of apoptotic cells
was assessed by CXP software.Cell cycle assay
Cells were plated in six-well culture dishes at concentra-
tions determined to yield 60–70% confluence within 24 h.
Cells were then treated with different concentrations of
apigenin (0–160 μM in DMSO). After 24 h, cells were
washed twice with PBS then centrifuged. The pellet was
fixed with 70% ethanol for 1 h at 4°C. The cells were
washed with PBS and resuspended with propidium iodide
solution (0.05 mg/mL) containing RNase, incubated at
room temperature in the dark for 30 min. DNA content
was then analyzed using the FC500 flow cytometer.Western blot analysis
Cell were harvested at 24 h following apigenin treatment,
washed, and lysed with lysis buffer (10 mmol/L Tris-HCl,
0.25 mol/ L sucrose, 5 mmol/L EDTA, 50 mmol/L NaCl,
30 mmol/L sodium pyrophosphate, 50 mmol/L NaF,
1 mmol/LNa3VO4, 1 mmol/L PMSF, and 2% cocktail
[pH 7.5]). Protein concentration in the resulting lysate was
determined using the bicinchoninic acid protein assay.
Appropriate amounts of protein (20–30 μg) were separated
by electrophoresis in 10–12% Tris-glycine polyacrylamide
gels and transferred to nitrocellulose membranes.
Membranes were blocked then incubated overnight with
the appropriate primary antibody at dilutions specified by
the manufacturer. They were next washed and incubated
with the corresponding HRP-conjugated secondary anti-
body at 1:1000 dilution in Tris-buffered saline-Tween 20
(10 mM Tris-Cl [pH 7.4], 150 mM NaCl, 0.1% Tween-20).
Bound secondary antibody was detected using an enhanced
chemiluminescence system (Pierce Biotechnology).Statistical analysis
Statistical significance was compared between various treat-
ment groups and controls using ANOVA. Data were con-
sidered statistically significant when P-values were <0.05.Competing interests
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